Researchers in Denmark have launched clinical trials investigating whether weight-loss injections like Wegovy can treat alcohol use disorder. Assessing 108 obese patients, the studies evaluate if glucagon-like peptide-1 receptor agonists reduce heavy drinking days, curb cravings, and improve liver health alongside talking therapy.
Clinical Trial Investigates GLP-1 for Alcohol Use Disorder
A recent clinical study conducted in Denmark has found that semaglutide—sold under the brand name Wegovy for weight loss and Ozempic for type 2 diabetes—can help curb drinking habits among patients with alcohol use disorder. The trial assessed 108 obese patients seeking treatment for alcohol problems. All participants received talking therapy, while half were given a placebo and the other half received a 2.4mg dose of semaglutide over 26 weeks, according to findings led by experts from the Mental Health Centre Copenhagen and Frederiksberg Hospital.
At the start of the trial, participants reported an average of 17 heavy drinking days over the preceding 30 days. After six months, patients administered semaglutide saw their heavy drinking days drop to roughly five per month, compared to nine days among the placebo group. Overall alcohol consumption also dropped more sharply in the treatment group, moving from an average of approximately 2,200g of alcohol over 30 days down to 650g, contrasted with a drop to 1,175g for those taking the dummy drug.
In Plain English: The Clinical Takeaway
- Mechanism of Action: Semaglutide is a GLP-1 receptor agonist, a drug class that mimics a natural gut hormone to regulate appetite. Researchers believe it also targets the biological pathways in the brain that drive addictive behaviors and cravings.
- Clinical Trial Design: This investigation was a placebo-controlled trial.
- Co-Occurring Conditions: The research specifically targets patients dealing with both obesity and alcohol dependency, two conditions that heavily compound physical decline.
Bridging Trials to National Health Systems
Building on these findings, researchers in the UK have initiated dedicated studies to evaluate how these medications can be deployed within public healthcare frameworks like the National Health Service (NHS). These investigations focus heavily on patients suffering from advanced liver complications.
According to Prof Guru Aithal, deputy director of the centre, the primary objective is determining if the drug can reduce alcohol intake while simultaneously driving weight loss, improving liver health, and enhancing quality of life. To qualify for the UK study, NHS patients must have a body mass index (BMI) of at least 30, a diagnosed alcohol use disorder, and clinical evidence of liver scarring or cirrhosis. Harmful drinking remains a leading cause of liver disease in the UK, a nation that has experienced higher rates of deaths from alcohol-related liver disease compared to other European countries over the past four decades.
“The combination of alcohol and obesity act together to speed up liver damage and death in patients, and both these conditions are difficult to treat with current medicines and counselling,” Prof Aithal explained. “I hope that we can successfully evidence the impact of weight-loss drugs to curb alcohol intake and demonstrate the cost effectiveness and potential for a new NHS treatment.”
Prof Ashwin Dhanda, a liver medicine specialist at the University of Plymouth, echoed this urgency. “We see patients who are dependent on alcohol and are obese every day, but there is currently no treatment that targets obesity and alcohol use at the same time,” he noted, adding that clinicians need to seize this therapeutic opportunity.
| Trial Parameter | Semaglutide Group (2.4mg) | Placebo Group |
|---|---|---|
| Sample Size | Approx. 54 participants | Approx. 54 participants |
| Duration | 26 Weeks | 26 Weeks |
| Heavy Drinking Days (30-day baseline vs. final) | Dropped from 17 days to ~5 days | Dropped from 17 days to ~9 days |
| Total Alcohol Consumption (30-day baseline vs. final) | Dropped from ~2,200g to 650g | Dropped from ~2,200g to 1,175g |
Expert Perspectives and Unresolved Questions
The broader medical community has welcomed the data while urging caution regarding long-term outcomes. Professor Anders Fink-Jensen, principal investigator of the Danish study, stated that the results suggest semaglutide influences the biological mechanisms underlying addiction alongside appetite regulation, opening the door to complementing existing treatments with a GLP-1 receptor-targeted approach. First author Dr Mette Kruse Klausen noted that reducing harmful drinking patterns makes a meaningful difference for a patient group facing a substantial risk of physical and mental complications.
In a linked commentary published in The Lancet, US academics emphasized that the importance of evaluating GLP-1 therapies for alcohol use disorder cannot be overstated, pointing to potentially substantial public health implications if forthcoming studies confirm efficacy across broader populations. Dr Marie Spreckley, research programme manager at the University of Cambridge, characterized the findings as encouraging early evidence for patients with co-occurring obesity and alcohol use disorder, while stressing that larger and longer-term trials in more diverse populations are needed before the approach informs routine clinical practice.
Matt Field, professor of psychology at the University of Sheffield, noted that the trial provides some of the strongest evidence yet that these medications help reduce alcohol consumption. However, he highlighted critical knowledge gaps. “There are still important gaps in our knowledge about the long-term effects of these drugs and who might benefit from them the most,” Prof Field stated, pointing out that the study lacked follow-up after treatment concluded. This leaves open the question of whether patients revert to heavy drinking once the medication is stopped.
References
- Klausen, M.K., et al. (2024). Semaglutide for alcohol use disorder: A randomized clinical trial. The Lancet.
Disclaimer: This article is for informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
